Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Personaliseret ultralyds hjernestimulering til depression (R61)

1. november 2026 opdateret af: Brian Mickey

Personaliseret ultralyds hjernestimulering til depression: En undersøgelse af målengagement og humørvirkninger

This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.

Studieoversigt

Detaljeret beskrivelse

This R61 project has 3 aims:

  1. To determine whether stimulation engages the subcallosal cingulate (SCC) in an intensity-dependent manner
  2. To examine the degree of specificity of neuromodulation by contrasting the neural effects of stimulating two spatially distinct targets versus sham
  3. To evaluate safety, tolerability, and side effects

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

39

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84108
        • University of Utah

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age 18-65, any gender.
  2. Primary diagnosis of DMS-5 major depressive disorder (MINI).
  3. Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).
  4. Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10.
  5. History of at least 2 failed trials of evidence-based antidepressant medication and/or psychotherapy (at least one trial during the current depressive episode).
  6. Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.
  7. For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.
  8. Capacity to provide informed consent; provision of a signed and dated consent form
  9. Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
  10. Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.
  11. Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.

Exclusion Criteria:

  1. History of serious brain injury or other neurologic disorder.
  2. Poorly managed general medical condition.
  3. Pregnant or breast feeding.
  4. Implanted device in the head or neck.
  5. MRI intolerance or contraindication.
  6. Brain stimulation treatment such as ECT, TMS, or VNS (past month).
  7. Recent change in antidepressant treatments (past month).
  8. 8. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and/or in the clinical judgement of the PI or a study psychiatrist
  9. Suicidal behavior (past year).
  10. Serious suicide attempt 33 (lifetime).
  11. Moderate-to-severe substance use disorder (MINI, past 3 months).
  12. Obsessive compulsive disorder, primary diagnosis (MINI, past month).
  13. Posttraumatic stress disorder, primary diagnosis (MINI, past month).
  14. Bipolar-spectrum disorder (MINI, lifetime).
  15. Schizophrenia-spectrum disorder (MINI, lifetime).
  16. Neurocognitive disorder (DSM-5, past year).
  17. Severe personality disorder.
  18. Clinically inappropriate for participation in the study as determined by the study team.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group 1: SCC-ALIC

Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the subgenual cingulate cortex (SCC) at the first stimulation visit, then LTFUS is delivered to the anterior limb of the internal capsule (ALIC) at the second stimulation visit.

Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex

Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule

Eksperimentel: Group 2: ALIC-SCC

Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the anterior limb of the internal capsule (ALIC) at the first stimulation visit, then LTFUS is delivered to the subgenual cingulate cortex (SCC) at the second stimulation visit.

Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex

Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Modulation of SCC activity during SCC stimulation
Tidsramme: Days 14, 21, 28

Functional MRI is used to quantify modulation of SCC activity during SCC stimulation

Days 14, 21, 28
Modulation of SCC activity during ALIC stimulation
Tidsramme: Days 14, 21

Functional MRI is used to quantify modulation of SCC activity during ALIC stimulation

Days 14, 21
Study dropout
Tidsramme: From enrollment to the end of participation at 7 weeks

Dropout or withdrawal due to stimulation-related adverse effects

From enrollment to the end of participation at 7 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PANAS-X
Tidsramme: Immediately before and after each LTFUS on Days 14, 21, 28

Positive and Negative Affect Schedule, Expanded Form

Immediately before and after each LTFUS on Days 14, 21, 28
MADRS
Tidsramme: Days 14, 21, 28, 35, 49

Montgomery-Asberg Depression Rating Scale

Days 14, 21, 28, 35, 49
HDRS-6
Tidsramme: Days 0, 14, 15, 21, 22, 28, 29, 35, 49

6-item Hamilton Depression Rating Scale

Days 0, 14, 15, 21, 22, 28, 29, 35, 49
IDS-SR
Tidsramme: Days 0, 14, 21, 28, 35, 49

Inventory of Depressive Symptomatology, Self-Rated

Days 0, 14, 21, 28, 35, 49
GAD-7
Tidsramme: Days 0, 14, 21, 28, 35, 49

7-item Generalized Anxiety Disorder Scale

Days 0, 14, 21, 28, 35, 49
YMRS
Tidsramme: Days 0, 14, 15, 21, 22, 28, 29, 35, 49

Young Mania Rating Scale

Days 0, 14, 15, 21, 22, 28, 29, 35, 49
C-SSRS
Tidsramme: Days 0, 14, 15, 21, 22, 28, 29, 35, 49

Columbia Suicide Severity Rating Scale, Screen Version

Days 0, 14, 15, 21, 22, 28, 29, 35, 49
GASE
Tidsramme: Days 15, 22, 29

Generic Assessment of Side Effects scale

Days 15, 22, 29
MoCA
Tidsramme: Days 14, 15, 49

Montreal Cognitive Assessment

Days 14, 15, 49

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Brian J Mickey, University of Utah

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. marts 2025

Primær færdiggørelse (Faktiske)

11. september 2026

Studieafslutning (Faktiske)

11. september 2026

Datoer for studieregistrering

Først indsendt

24. marts 2025

Først indsendt, der opfyldte QC-kriterier

24. marts 2025

Først opslået (Faktiske)

30. marts 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IRB_00148802R61
  • R61MH134943 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner